Glutathione: The Master Antioxidant Tripeptide and Cellular Defense Research

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Glutathione?

Glutathione (abbreviated GSH for its reduced form) is a tripeptide composed of three amino acids — glutamic acid, cysteine, and glycine — joined by an unusual gamma-peptide bond between the gamma-carboxyl group of glutamate and the amino group of cysteine, followed by a standard peptide bond to glycine. This gamma-linkage is critical: it renders glutathione resistant to degradation by most intracellular peptidases, allowing it to accumulate to millimolar concentrations inside cells — far higher than typical peptide concentrations.

Often called the "master antioxidant," glutathione is the most abundant non-protein thiol in mammalian cells, present at concentrations of 1–10 mM in the cytosol depending on cell type. The liver, in particular, maintains the highest GSH concentrations (5–10 mM) consistent with its central role in detoxification. GSH participates in a vast array of cellular processes beyond simple antioxidant defense, including DNA synthesis and repair, protein function regulation, prostaglandin synthesis, and amino acid transport. For context on anti-inflammatory compounds, see our guide to anti-inflammatory peptides.

Property	Detail
Full Name	Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine)
Abbreviation	GSH (reduced), GSSG (oxidized)
Amino Acids	3 (Glu-Cys-Gly with gamma-peptide bond)
Molecular Weight	~307 Da
Active Group	Cysteine thiol (-SH) group
Intracellular Concentration	1–10 mM (varies by tissue)
GSH:GSSG Ratio (healthy cells)	100:1 to 500:1
Synthesis	Two-step: GCL (rate-limiting) then GSS
Rate-Limiting Factor	Cysteine availability

Mechanism of Action

The biological activity of glutathione centers on the thiol (-SH) group of its cysteine residue. This reactive sulfhydryl group can donate electrons to neutralize reactive oxygen species (ROS) and reactive nitrogen species (RNS), becoming oxidized in the process. Two oxidized glutathione molecules (GS-) join to form glutathione disulfide (GSSG), which is then recycled back to GSH by the enzyme glutathione reductase using NADPH as a cofactor.

Antioxidant Functions

• Direct ROS scavenging: GSH directly neutralizes superoxide, hydroxyl radicals, and peroxides through non-enzymatic reactions with its thiol group.
• Glutathione peroxidase system: GSH serves as the electron donor for glutathione peroxidase (GPx) enzymes, which catalyze the reduction of hydrogen peroxide and lipid hydroperoxides to water and corresponding alcohols.
• Vitamin recycling: GSH reduces oxidized vitamin C (dehydroascorbate) back to ascorbate, and participates indirectly in vitamin E recycling, creating an interconnected antioxidant network.
• Protein thiol maintenance: GSH maintains protein cysteine residues in their reduced state through glutaredoxin-mediated deglutathionylation, preventing oxidative protein damage and dysfunction.

Detoxification Functions

• Phase II conjugation: Glutathione S-transferase (GST) enzymes catalyze the conjugation of GSH to electrophilic toxins, drugs, and carcinogens, rendering them water-soluble for excretion via bile or urine.
• Heavy metal binding: GSH chelates heavy metals (mercury, lead, arsenic, cadmium) through thiol-metal coordination, facilitating their excretion.
• Drug metabolism: GSH conjugation is a major pathway for the metabolism and clearance of numerous pharmaceutical agents, including acetaminophen (whose toxic metabolite NAPQI is detoxified by GSH conjugation).

Research and Clinical Context

Age-Related GSH Decline

Plasma and tissue GSH levels decline progressively with age, typically beginning around age 45–50. This decline is attributed to reduced synthesis (decreased gamma-glutamylcysteine ligase activity), increased oxidative consumption, and diminished recycling capacity. The age-related GSH decline correlates with increased susceptibility to oxidative stress, infections, and chronic diseases of aging.

The NAC vs. Oral GSH Debate

The most practical question in glutathione supplementation is whether to supplement with GSH directly or with its precursor N-acetylcysteine (NAC). Traditional pharmacological teaching held that oral GSH is poorly bioavailable — degraded by gamma-glutamyltransferase in the intestinal lumen and brush border before absorption. NAC, by contrast, is well absorbed and provides the rate-limiting cysteine substrate for intracellular GSH synthesis.

However, more recent studies have challenged this view. A randomized controlled trial published in the European Journal of Nutrition (2015) demonstrated that oral GSH supplementation at 250–1,000 mg/day for 6 months increased blood GSH levels and reduced oxidative stress markers in healthy adults. Liposomal GSH formulations have shown improved bioavailability in some pharmacokinetic studies, though the evidence remains mixed and methodology varies between studies.

IV Glutathione

Intravenous glutathione bypasses the oral bioavailability question entirely, delivering reduced GSH directly to the bloodstream. IV GSH has been investigated in Parkinson's disease (based on the observation that substantia nigra GSH is depleted in PD patients), chronic liver disease, and as a component of integrative detoxification protocols. However, controlled clinical trials have generally not supported sustained benefit from IV GSH in these conditions, and the very short plasma half-life of exogenous GSH (minutes) raises questions about the duration of therapeutic effect.

Disease Associations

Low GSH levels have been associated with a remarkably wide range of conditions: neurodegenerative diseases (Parkinson's, Alzheimer's), liver disease, pulmonary disease (COPD, cystic fibrosis, ARDS), HIV/AIDS, diabetes, cancer, and cardiovascular disease. Whether GSH depletion is a cause, consequence, or bystander of these conditions varies by context and remains an active area of investigation.

Safety and Tolerability

Glutathione has an excellent safety profile as a supplement. The FDA classifies it as Generally Recognized as Safe (GRAS). Oral supplementation at doses up to 1,000 mg/day has been used in clinical studies without significant adverse effects. IV glutathione has been administered in clinical settings with generally good tolerability, though allergic reactions, nausea, and headache have been reported. NAC, as a GSH precursor, is well-established with both supplement and pharmaceutical uses (IV NAC is the standard treatment for acetaminophen overdose).

One theoretical concern with high-dose antioxidant supplementation is the potential to interfere with ROS-dependent signaling that serves beneficial functions, including exercise adaptations and immune cell activation. Whether this concern is clinically relevant at typical supplementation doses has not been definitively established.

Regulatory Status

Glutathione is available as an over-the-counter dietary supplement in oral (capsules, liposomal, sublingual), topical, and nebulized forms. It is not FDA-approved as a drug for any specific indication. IV glutathione is administered off-label in clinical settings, typically through integrative medicine practices. NAC is available both as a dietary supplement and as an FDA-approved drug (Acetadote for acetaminophen toxicity; Mucomyst for mucous management). The regulatory landscape for NAC supplements has been subject to FDA scrutiny regarding its classification as a dietary supplement vs. drug.